Dermata Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

DRMA$0.71-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

	For the year endedDecember 31,
2023 · 2022
Cash flows from operating activities:
Net loss	$(7,794,690)		$(9,610,913)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	522,082		930,325
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets	162,695		121,940
Accounts payable	369,326		(18,543)
Accrued and other current liabilities	331,656		(256,973)
Total adjustments to reconcile net loss to cash used in operations	1,385,759		776,749
Net cash used in operating activities	(6,408,931)		(8,834,164)
Cash flows from financing activities:
Proceeds from issuance of Common Stock and warrants, net of issuance costs	7,605,625		4,276,365
Proceeds from exercise of pre-funded warrants	187		287
Payment for fractional shares in reverse stock split	(40)		-
Net cash provided by financing activities	7,605,772		4,276,652
Net increase (decrease) in cash and cash equivalents	1,196,841		(4,557,512)
Cash and cash equivalents at beginning of period	6,241,294		10,798,806
Cash and cash equivalents at end of period	$7,438,135		$6,241,294
Supplemental disclosure:
Cash paid for taxes	$950		$950
Non-cash financing activities:
Incremental fair value of March 2023 warrant modification	$144,765	$	-
Incremental fair value of November 2023 warrant inducement	$2,995,343	$	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.